Translational Biomedicine©

14 (5) 2023: 001-002 • Perspective

Fetal and neonatal stem cells: Derivation, characterization and differentiation for clinical use with *in vivo* validation

Vikki Bunton*

Department of Neurology, Perth University, Perth, Australia

INTRODUCTION

Stem cells have captivated the scientific community a nd the world at large due to their remarkable potential to revolutionize the field of medicine. Among these, fetal and neonatal stem cells hold particular promise. These cells, derived from early developmental stages, possess unique characteristics that make them attractive candidates for various therapeutic applications. In this article, we will explore the derivation, characterization and differentiation of fetal and neonatal stem cells, as well as their *in vivo* validation for clinical use.

Fetal stem cells

Fetal stem cells are obtained from the tissues of developing embryos. These cells are pluripotent, meaning t hey can give rise to various cell types in the body. They are typically harvested during the first trimester of pregnancy, as this is when the embryos are most abundant in pluripotent cells. The primary sources of fetal stem cells are the fetal liver, bone marrow and the umbilical cord blood.

Derivation of fetal stem cells

The most common method for obtaining fetal stem cells is through the isolation of cells from the umbilical cord blood. This process is safe, non-invasive and poses no harm to the fetus or the mother. After childbirth, the umbilical cord is clamped and cut and the cord blood is collected and processed to isolate hematopoietic stem cells, which are responsible for forming blood cells. These cells can be cryopreserved and stored for future medical use.

DESCRIPTION

Characterization of fetal stem cells

Fetal stem cells exhibit distinct characteristics that make them attractive for clinical use. They are characterized by their pluripotency, which means they can differentiate into various cell types, such as neurons, muscle cells and blood cells. Additionally, fetal stem cells have a high proliferation rate, which allows for the generation of a significant number of cells in a relatively short period.

Differentiation of fetal stem cells

Fetal stem cells can be differentiated into specific cell types through various methods, including the use of growth factors, cytokines and culture conditions. For example,

Address for correspondence:

Vikki Bunton,
Department of Neurology, Perth University, Perth, Australia,
E-mail: vbunton@swi.edu.au

Word count: 1027 **Tables:** 00 **Figures:** 0 **References:** 00

Received: 04.09.2023, Manuscript No. iptb-23-14182;
Editor assigned: 07.09.2023, PreQC No. P-14182;
Reviewed: 21.09.2023, QC No. Q-14182;
Revised: 03.10.2023, Manuscript No. R-14182;
Published: 31.10.2023, Invoice No. J-14182

these cells can be directed to differentiate into neurons, offering potential treatments for neurodegenerative diseases. Furthermore, their differentiation potential allows for the development of therapeutic strategies for a wide range of medical conditions, including cardiovascular disorders, diabetes and regenerative medicine.

In vivo validation of fetal stem cells

In vivo validation is a crucial step in assessing the effectiveness and safety of fetal stem cells for clinical use. Numerous studies have explored the transplantation of fetal stem cells into animal models to evaluate their therapeutic potential.

One notable example of *in vivo* validation comes from research on fetal neural stem cells for the treatment of neurodegenerative diseases. In a study published in the journal "Nature Biotechnology," fetal neural stem cells were transplanted into a mouse model of Parkinson's disease. The results showed s ignificant im provements in motor function and the survival of dopaminergic neurons, suggesting that fetal neural stem cells hold promise for treating this debilitating condition.

Similarly, fetal hematopoietic stem cells have been successfully transplanted into animal models to treat various blood disorders. In a study published in "Science Translational Medicine," researchers used fetal hematopoietic stem cells to treat a mouse model of sickle cell anemia. The transplanted cells effectively ɐ placed the defective blood cells, resulting in improved health outcomes for the animals.

Neonatal stem cells

Neonatal stem cells are derived from the tissues of newborns. These cells are particularly valuable due to their regenerative capacity and potential to repair damaged tissues. The primary sources of neonatal stem cells are the umbilical cord blood, umbilical cord tissue and placental tissue.

Derivation of neonatal stem cells

Umbilical cord blood and tissue are rich sources of neonatal stem cells. Cord blood contains hematopoietic stem cells, while cord tissue and placental tissue harbor mesenchymal stem cells. These cells can be easily collected after childbirth without causing any harm to the baby or the mother.

Characterization of neonatal stem cells

Neonatal stem cells possess several distinct characteristics that make them promising candidates for clinical applications. Hematopoietic stem cells from cord blood can differentiate into various blood cell types, making them valuable for treating hematologic disorders. Mesenchymal stem cells from cord tissue and placental tissue exhibit immunomodulatory properties, anti-inflammatory effects and the ability to differentiate into bone, cartilage and fat cells.

Differentiation of neonatal stem cells

Neonatal stem cells can be differentiated into various cell types, depending on their source and specific culture conditions. Hematopoietic stem cells can be directed to become red blood cells, white blood cells or platelets, addressing a wide range of blood-related diseases. Mesenchymal stem cells, on the other hand, can be guided to differentiate i nto b one-forming o steoblasts, cartilage-producing chondrocytes and adipocyte-forming fat cells, offering potential treatments for orthopedic and musculoskeletal conditions.

In vivo validation of neonatal stem cells

The therapeutic potential of neonatal stem cells has been extensively explored through *in vivo* validation studies. These experiments have demonstrated the safety and efficacy of neonatal stem cells in various disease models.

For instance, a study published in the journal "Stem cells translational medicine" investigated the use of umbilical cord blood-derived hematopoietic stem cells in a mouse model of leukemia. The results showed that the transplanted cells effectively restored normal blood cell production and extended the survival of the animals, providing strong evidence for the clinical utility of neonatal stem cells in treating hematologic malignancies.

Moreover, mesenchymal stem cells derived from umbilical cord tissue have been evaluated in animal models of orthopedic injuries. In a study published in the "journal of orthopaedic research," researchers transplanted neonatal mesenchymal stem cells into a rat model of spinal cord injury. The treated animals showed improved functional recovery and reduced inflammation, highlighting the potential of neonatal stem cells for spinal cord regeneration.

CONCLUSION

Fetal and neonatal stem cells offer great promise for revolutionizing regenerative medicine and treating a wide range of diseases and conditions. These cells, characterized by their pluripotency and regenerative potential, have been validated in various *in vivo* studies, demonstrating their therapeutic efficacy. However, challenges such as ethical considerations, immune rejection and safety concerns must be addressed before these therapies can be widely adopted. As research in this field continues to advance, it is crucial to maintain a careful balance between innovation and ethical responsibility.